PI3K/AKT inhibition combined with different types of endocrine drugs, such as tamoxifen, AIs, and fulvestrant, is a new strategy for ER+ breast cancer treatment (Sabine, et al., 2014; Hanamura and Hayashi, 2018). This evidence concerns the gene PIK3CA and breast carcinoma.